Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 13,436 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Insmed Stock Down 1.9 %

Shares of NASDAQ INSM traded down $1.43 during midday trading on Monday, hitting $73.23. 1,402,956 shares of the stock traded hands, compared to its average volume of 2,436,028. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The business has a 50 day moving average price of $74.65 and a two-hundred day moving average price of $50.60. The company has a market cap of $10.88 billion, a PE ratio of -14.28 and a beta of 1.11.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The firm had revenue of $90.34 million for the quarter, compared to the consensus estimate of $87.95 million. During the same period in the previous year, the firm posted ($1.78) earnings per share. Insmed’s quarterly revenue was up 17.0% compared to the same quarter last year. On average, equities analysts predict that Insmed Incorporated will post -5.42 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on INSM. Evercore ISI lifted their target price on Insmed from $42.00 to $75.00 and gave the stock an “outperform” rating in a report on Friday, June 21st. Barclays increased their target price on shares of Insmed from $40.00 to $63.00 and gave the company an “overweight” rating in a research report on Wednesday, May 29th. Morgan Stanley raised their price target on shares of Insmed from $60.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, July 12th. Guggenheim upped their price objective on shares of Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Finally, Truist Financial lowered their target price on shares of Insmed from $88.00 to $85.00 and set a “buy” rating for the company in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.19.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. First Horizon Advisors Inc. raised its position in Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 287 shares during the last quarter. EntryPoint Capital LLC bought a new stake in shares of Insmed in the 1st quarter worth $33,000. Fidelis Capital Partners LLC purchased a new position in Insmed during the first quarter worth about $34,000. CWM LLC boosted its holdings in Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 155 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Insmed by 8.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 135 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.